Unknown

Dataset Information

0

Effective Small Interfering RNA Therapy to Treat CLCN7-dependent Autosomal Dominant Osteopetrosis Type 2.

ABSTRACT: In about 70% of patients affected by autosomal dominant osteopetrosis type 2 (ADO2), osteoclast activity is reduced by heterozygous mutations of the CLCN7 gene, encoding the ClC-7 chloride/hydrogen antiporter. CLCN7(G215R)-, CLCN7(R767W)-, and CLCN7(R286W)-specific siRNAs silenced transfected mutant mRNA/EGFP in HEK293 cells, in RAW264.7 cells and in human osteoclasts, with no change of CLCN7(WT) mRNA and no effect of scrambled siRNA on the mutant transcripts. Osteoclasts from Clcn7(G213R) ADO2 mice showed reduced bone resorption, a condition rescued by Clcn7(G213R)-specific siRNA. Treatment of ADO2 mice with Clcn7(G213R)-specific siRNA induced increase of bone resorption variables and decrease of trabecular bone mass, leading to an overall improvement of the osteopetrotic bone phenotype. Treatment did not induce overt adverse effects and was effective also with siRNAs specific for other mutants. These results demonstrate that a siRNA-based experimental treatment of ADO2 is feasible, and underscore a translational impact for future strategy to cure this therapeutically neglected form of osteopetrosis.

SUBMITTER: Capulli M 

PROVIDER: S-EPMC4877447 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Effective Small Interfering RNA Therapy to Treat CLCN7-dependent Autosomal Dominant Osteopetrosis Type 2.

Capulli Mattia M   Maurizi Antonio A   Ventura Luca L   Rucci Nadia N   Teti Anna A  

Molecular therapy. Nucleic acids 20150901

In about 70% of patients affected by autosomal dominant osteopetrosis type 2 (ADO2), osteoclast activity is reduced by heterozygous mutations of the CLCN7 gene, encoding the ClC-7 chloride/hydrogen antiporter. CLCN7(G215R)-, CLCN7(R767W)-, and CLCN7(R286W)-specific siRNAs silenced transfected mutant mRNA/EGFP in HEK293 cells, in RAW264.7 cells and in human osteoclasts, with no change of CLCN7(WT) mRNA and no effect of scrambled siRNA on the mutant transcripts. Osteoclasts from Clcn7(G213R) ADO2  ...[more]

Similar Datasets

Unknown Novel CLCN7 mutation identified in a Han Chinese family with autosomal dominant osteopetrosis-2.
| S-EPMC4955969 | biostudies-literature
Unknown Autosomal dominant osteopetrosis associated with renal tubular acidosis is due to a CLCN7 mutation.
| S-EPMC5132132 | biostudies-literature
Unknown Genetic Analysis of CLCN7 in an Old Female Patient with Type II Autosomal Dominant Osteopetrosis.
| S-EPMC6145957 | biostudies-literature
Unknown Extra-skeletal manifestations in mice affected by <i>Clcn7</i>-dependent autosomal dominant osteopetrosis type 2 clinical and therapeutic implications.
| S-EPMC6559989 | biostudies-literature
Unknown Novel CLCN7 compound heterozygous mutations in intermediate autosomal recessive osteopetrosis.
| S-EPMC5559424 | biostudies-literature
Unknown Enhanced but hypofunctional osteoclastogenesis in an autosomal dominant osteopetrosis type II case carrying a c.1856C>T mutation in <i>CLCN7</i>.
| S-EPMC5126728 | biostudies-literature
Unknown Transcriptome sequencing identifies a noncoding, deep intronic variant in CLCN7 causing autosomal recessive osteopetrosis.
| S-EPMC7549584 | biostudies-literature
Unknown Functional nanostructures for effective delivery of small interfering RNA therapeutics.
| S-EPMC4183999 | biostudies-literature
Unknown Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models.
| S-EPMC3889206 | biostudies-literature
Unknown Radiographic imaging, densitometry and disease severity in Autosomal dominant osteopetrosis type 2.
| S-EPMC8009803 | biostudies-literature